Nav: Home

Rettsyndrome.org reaches milestone of $40 million in research funding

January 09, 2017

(Cincinnati, OH) The International Rett Syndrome Foundation, now doing business as Rettsyndrome.org, announces today that Rettsyndrome.org has reached a milestone in research funding. The leading foundation for Rett research has distributed over $40 million dollars to accelerate treatments for Rett syndrome.

In December 2016, an additional $2M was granted to support four breakthrough human clinical trials for potential pharmacological interventions. Rettsyndrome.org also funded the renewal of two database grants and granted an extension of the Scout Program for drug discovery efforts.

Rettsyndrome.org continues to be the undisputed non-governmental leader in driving clinical research with results. In early 2016, Rettsyndrome.org funded the largest multi-site human clinical trial of Neuren Pharmaceutical's drug trofinetide. This trial completed enrollment in late 2016 and results from the trofinetide drug trial should be available in mid-2017. Phase 2 IGF-1 trial at Boston Children's Hospital has also completed enrollment and all study visits. Results will be available in 2017.

In late 2016, Newron pharmaceuticals began enrollment throughout the US, UK, Italy, and India for their study of Sarizotan, a potential treatment for breathing abnormalities found in Rett syndrome. This is the first pivotal Phase 2/3 clinical trial located at multiple sites.

Rettsyndrome.org's Chief Science Officer, Steve Kaminsky, PhD, shares, "With an investment of over $40 million dollars into understanding, treating and curing Rett syndrome our organization continues to move the bar in helping all of those suffering with Rett syndrome. Our recent investments into clinical trials bring us closer to our goal of changing the lives of those with Rett syndrome NOW. Together with all of our wonderful donors we are bring about changes in this devastating disorder."
-end-
About Rettsyndrome.org

Rettsyndrome.org is the most comprehensive nonprofit organization dedicated to accelerating research of treatments and a cure for Rett syndrome to accelerate full spectrum research to treat and cure Rett syndrome while empowering the community through knowledge and connectivity.

As the world's leading private funder of Rett syndrome research, Rettsyndrome.org has funded over $40M in high-quality, peer-reviewed research grants and programs to date. The organization hosts the largest global gathering of Rett researchers and clinicians to establish research direction for the future. Rettsyndrome.org, a 501(c)3 organization, has earned Charity Navigator's most prestigious 4 star rating year after year. To learn more about our work and Rett syndrome, visit http://www.rettsyndrome.org or call (800) 818-7388 (RETT).

Rettsyndrome.org

Related Rett Syndrome Articles:

Neuren's Phase 2 trofinetide trial shows significant benefit in pediatric Rett syndrome
The International Rett Syndrome Foundation, now doing business as Rettsyndrome.org, announces today that Neuren Pharmaceuticals reported that trofinetide had significant clinical benefit in their Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15.
In Rett syndrome model, team shows how adult learning is impaired in females
In mouse models of Rett syndrome -- which in humans is seen overwhelmingly in females -- researchers have demonstrated how failure of Mecp2, the mouse equivalent of the human gene of the same name, has biological consequences that prevent adult females from learning how to gather newborn pups in the days immediately following the pups' birth.
Double effort against Rett's syndrome
Although our genes normally come in pairs but sometimes one of them is missing (haploinsufficiency) leading sometimes to serious diseases.
Rett Syndrome study finds mechanisms underlying its visual deficits
This study helps explain why rhIGF1 has therapeutic effects for RTT patients.
Insights into neurons that cause symptoms of Rett syndrome could guide new therapy search
Two studies in mice from Baylor College of Medicine, Texas, reveal new insights into neurons that mediate symptoms typical of the postnatal neurological disorder Rett syndrome.
New drug target for Rett syndrome
Harvard Stem Cell Institute researchers have identified a faulty signaling pathway that, when corrected, in mice ameliorates the symptoms of Rett syndrome, a devastating neurological condition.
Rett Syndrome Association of Massachusetts and Rettsyndrome.org continue their partnership
The Rett Syndrome Association of Massachusetts and Rettsyndrome.org announce today their renewed commitment to work together to defeat Rett syndrome.
In mice, experimental drug treatment for Rett syndrome suggests the disorder is reversible
A team at CSHL has developed a strikingly new approach for treating Rett syndrome, a devastating autism spectrum disorder.
New studies contradict earlier findings on Rett syndrome
Scientists at the University of Iowa, Baylor College of Medicine, Fred Hutchinson Cancer Research Center, and the University Medical Center Gottingen, in Germany, show that bone marrow transplant does not rescue mouse models of Rett syndrome, a severe neurological disease that affects very young girls.
New research implicates immune system in Rett syndrome
New research by investigators at the University of Massachusetts Medical School suggests the immune system plays an unsuspected and surprising role in the progression of Rett syndrome, a severe neurological disorder affecting children.

Related Rett Syndrome Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".